Atopic Dermatitis / Atopic Eczema – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of atopic dermatitis/atopic eczema (AD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of AD for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the major mature pharmaceutical markets.
Clarivate Epidemiology’s AD forecast will answer the following questions:
- Of all people with AD, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
- Of all people diagnosed with AD, how many in each of the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of AD over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology provides at least 20 years of forecast data for the following AD populations:
- Total 12-month prevalent cases of AD.
- Total 12-month prevalent cases of AD by severity.
- Diagnosed 12-month prevalent cases of AD.
- Diagnosed 12-month prevalent cases of AD by severity.
- Diagnosed 12-month prevalent cases of AD by treatment status.
Note: Coverage may vary by country.
Table of contents
- Atopic Dermatitis / Atopic Eczema - Epidemiology - Mature Markets
- Epidemiology data
- Methods
- Literature review (studies included in/excluded from the analyses of atopic dermatitis/atopic eczema)
- Twelve-Month Total Prevalent Cases
- Twelve-Month Total Prevalent Cases by Severity
- Diagnosed 12-Month Prevalent Cases
- Diagnosed Drug-Treated 12-Month Prevalent Cases
- Risk / protective factors applied to disease forecast models
- Reference materials
